Welcome to our dedicated page for Aileron Therapeutics news (Ticker: ALRN), a resource for investors and traders seeking the latest updates and insights on Aileron Therapeutics stock.
About Aileron Therapeutics Inc.
Aileron Therapeutics Inc. (NASDAQ: ALRN) is a clinical-stage biopharmaceutical company dedicated to advancing a novel pipeline of first-in-class medicines that address significant unmet medical needs in orphan pulmonary, fibrotic, and oncology indications. With a strong foundation in peptide therapeutics, Aileron is at the forefront of developing innovative therapies designed to improve patient outcomes in challenging and underserved medical conditions.
Core Product Pipeline
LTI-03: Aileron's lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism of action targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. Currently in clinical development, LTI-03 has shown promise in treating idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. The therapy's unique approach aims to not only slow disease progression but potentially restore healthy lung function.
LTI-01: Another key asset in Aileron's pipeline, LTI-01, is a proenzyme developed for loculated pleural effusions. Having completed Phase 1b and Phase 2a clinical trials, LTI-01 has received Orphan Drug Designation in both the U.S. and EU, as well as Fast Track Designation in the U.S., underscoring its potential to address critical unmet needs in this condition.
ALRN-6924: Previously a lead oncology candidate, ALRN-6924 is a clinical-stage therapy that reactivates the tumor-suppressing protein p53 by targeting MDMX and MDM2. This innovative approach has positioned ALRN-6924 as the first and only clinical-stage drug targeting MDMX, with potential applications in rare cancers like retinoblastoma.
Market Position and Competitive Edge
Aileron Therapeutics operates in the highly specialized fields of peptide-based therapeutics and orphan disease indications. By focusing on first-in-class therapies, the company differentiates itself from competitors through its innovative mechanisms of action and targeted approach to high-need patient populations. Its strategic focus on orphan diseases, supported by Orphan Drug and Fast Track designations, positions it to capitalize on regulatory incentives and market exclusivity.
Industry Significance
As a pioneer in peptide therapeutics, Aileron Therapeutics is contributing to the advancement of treatments for complex diseases with limited existing options. Its commitment to addressing unmet medical needs in IPF, fibrosis, and oncology aligns with broader industry trends emphasizing innovation in rare and life-threatening diseases. With a robust clinical pipeline and a focus on leveraging cutting-edge science, Aileron is poised to make a meaningful impact on patient care and the biopharmaceutical landscape.
Aileron Therapeutics (NASDAQ: ALRN) provided a business update on January 5, 2022, focusing on its clinical trial plans for its chemoprotective agent ALRN-6924. The company aims to initiate a Phase 1b trial in neoadjuvant breast cancer by 1H22, with interim data expected in 4Q22. Aileron also anticipates interim results from an ongoing NSCLC trial in 2Q22 and topline results in 4Q22. In 2021, Aileron secured 11 new patents, enhancing its intellectual property portfolio to over 170 patents globally, reinforcing its commitment to developing safer chemotherapy alternatives.
Aileron Therapeutics (Nasdaq: ALRN) announced that Dr. Manuel Aivado will present a company overview at two upcoming virtual conferences: the H.C. Wainwright BIOCONNECT Conference from January 10-12, 2022, and the Emerging Growth Conference on January 5, 2022. The H.C. Wainwright presentation will be available on-demand starting January 10 at 7:00 a.m. ET. Aileron's ALRN-6924 is a first-in-class chemoprotective agent targeting p53-mutated cancers, aiming to improve chemotherapy tolerability while preserving healthy cells.
Aileron Therapeutics (NASDAQ:ALRN) expressed deep sorrow over the passing of Nobel Laureate Robert H. Grubbs, Ph.D., a member of its Scientific Advisory Board since 2011. Grubbs, a prominent chemist, significantly influenced Aileron's stapled peptide technology and the chemoprotective agent ALRN-6924.
His contributions to metathesis reactions enabled the development of specialized drugs and plastics. Aileron vows to honor his legacy by advancing ALRN-6924, aimed at improving the chemotherapy experience for patients with p53-mutated cancers.
Aileron Therapeutics (NASDAQ:ALRN) continues its Phase 1b trial of ALRN-6924 for p53-mutated non-small cell lung cancer (NSCLC). Planned data readouts include interim results in 2Q22 and topline results in 4Q22. As of September 30, 2021, the company reported $52.2 million in cash, expected to fund operations until mid-2023. R&D expenses rose to $4.3 million, while net loss increased to $6.7 million. ALRN-6924 aims to protect healthy cells from chemotherapy-induced side effects, potentially addressing a critical need for cancer patients.
Aileron Therapeutics has presented new preclinical data at the AACR-NCI-EORTC conference, highlighting ALRN-6924's potential as a chemoprotective and radioprotective agent for patients with p53-mutated cancers undergoing chemotherapy. The data shows that ALRN-6924 activates p21, which may help protect healthy cells from chemotherapy and radiation-induced toxicities. The company is currently conducting a Phase 1b clinical trial in patients with advanced non-small cell lung cancer, aiming to reduce chemotherapy side effects while maintaining efficacy.
Aileron Therapeutics (ALRN) announced new preclinical data on its investigational drug ALRN-6924, showcasing its potential as a radioprotective agent against radiation-induced toxicities. ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor, aims to protect healthy cells during chemotherapy for patients with p53-mutated cancers. The data will be presented at the AACR-NCI-EORTC conference on October 7, 2021. The Phase 1b trial for ALRN-6924 is underway, evaluating its effectiveness in non-small cell lung cancer patients treated with carboplatin and pemetrexed.
Aileron Therapeutics (ALRN) announced positive outcomes from its Phase 1b trial of ALRN-6924 in small cell lung cancer (SCLC) patients receiving topotecan, showing significant reductions in chemotherapy-induced neutropenia, thrombocytopenia, and anemia compared to historical controls. Preliminary findings from a Phase 1 pharmacology study confirmed the optimal dose of ALRN-6924 at 0.3 mg/kg, demonstrating its pharmacodynamic effects. These results inform future studies of ALRN-6924 as a chemoprotective agent across various p53-mutated cancers.
Aileron Therapeutics (Nasdaq: ALRN) announced its upcoming presentations at the ESMO Virtual Congress 2021, including preliminary data from a Phase 1 study of ALRN-6924 in healthy volunteers and final results from a Phase 1b study in patients with small cell lung cancer (SCLC) receiving topotecan. ALRN-6924 aims to protect healthy cells from chemotherapy-induced side effects while targeting cancer cells. The findings support ongoing and future studies in patients with p53-mutated cancers.
Aileron Therapeutics (Nasdaq: ALRN) announced that CEO Manuel Aivado will present at the H.C. Wainwright Virtual Global Investment Conference from September 13-15, 2021. His presentation will cover the progress of ALRN-6924, a selective chemoprotective agent targeting p53-mutated cancers. The on-demand presentation will be available to registered attendees starting September 13, 2021, at 7 AM ET and accessible for 30 days on Aileron's website. Aileron aims to enhance chemotherapy tolerability and improve patients' quality of life by protecting healthy cells during treatment.
Aileron Therapeutics (Nasdaq: ALRN) reported initial findings from its study of ALRN-6924, showcasing that a 0.3 mg/kg dose was well tolerated and induced p53-mediated p21 in normal bone marrow cells. This Phase 1b trial aims to evaluate ALRN-6924 as a chemoprotective agent for patients with advanced p53-mutated non-small cell lung cancer (NSCLC). Nearly 1 million patients in the U.S. are diagnosed yearly with p53-mutated cancers. Aileron also plans to present more data from this study at the upcoming ESMO Congress in September 2021.
FAQ
What is the current stock price of Aileron Therapeutics (ALRN)?
What is the market cap of Aileron Therapeutics (ALRN)?
What does Aileron Therapeutics Inc. specialize in?
What are Aileron's key product candidates?
How does LTI-03 work?
What regulatory designations has Aileron received?
What differentiates Aileron from its competitors?
What is ALRN-6924, and what does it target?
What is idiopathic pulmonary fibrosis (IPF)?
What are the risks associated with Aileron's clinical programs?
